Whole genome sequencing in the clinic: New opportunities for precision diagnostics, disease surveillance and biomarker discovery

We are very pleased to welcome Professor Elli Papaemmanouil. She is an Associate Attending at the Computational Oncology Service, Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center, New York and Associate Director for the Center of Hematological Malignancies.

Her research focuses on the study of acquired mutations in cancer development and the integration of complex genomics into clinical practice, using techniques in clinical, computational, molecular and mathematical research.

Find out more about her research

In collaboration with the Research Institute, McGill University Health Center

About the speaker

Elli Papaemmanouil, PhD

Professor Elli Papaemmanouil is an Associate Attending at the Computational Oncology Service, Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center and is also serving as Associate Director for the Center of Hematological Malignancies. She has a master’s degrees in human molecular genetics from the University of Glasgow, UK and a PhD in population genetics at the Institute of Cancer Research at the University of London.

Her research involved the characterization of germline predisposition loci in childhood ALL by means of population genome wide association studies. Pr. Papaemmanouil pursued postdoctoral research at the Wellcome Trust Sanger Institute under the mentorship of Peter Campbell where she led research into the discovery of cancer gene drivers of hematological neoplasms.

More recently, Professor Papaemmanouil has developed experimental and analytical methods to support molecular characterization of large patient cohorts and study the genetic and clinical inter-relationships of leukemias.

She currently leads large population genomic profiling studies in myeloid neoplasms (AML, MDS, MPN) and in Acute Lymphoblastic Leukemia with the aim to characterize how the molecular architecture of the disease and the corresponding clonal relationships determine clinical phenotype and response to therapy. She leads the computational oncology group for the center of heme malignancies at MSKCC and the pediatrics.

About CRCHUM's Prestige conferences

The CRCHUM Prestige Conferences are presented by world-renowned speakers in their field of expertise.

This Prestige conferences offer a broad perspective on a scientific topic in a language that is clear and accessible to all participants. They are mainly aimed at the scientific community, including participants who have no prior knowledge of the topic.